16 unknown. 16 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Unknown 16 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 41 | 2023-11-01 | 2023-11-18 |
| Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC Envafolimab+Gemox - Gallbladder Cancer | Phase 2 | Unknown | Eastern Hepatobiliary Surgery Hospital | 30 | 2023-03-17 | 2023-09-15 |
| Addition of Everolimus to Standard of Care in Carcinoma Gallbladder Everolimus 10 mg, Standard of care - Gallbladder Cancer | Phase 2 / Phase 3 | Unknown | Banaras Hindu University | 56 | 2022-11-01 | 2024-08-13 |
| Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX - Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 60 | 2022-09-08 | 2022-11-17 |
| Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers Toripalimab plus Lenvatinib - Advanced Biliary Tract Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 44 | 2020-08-11 | 2023-03-29 |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Chemotherapy, Observation, Immunotherapy - Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-sen University | 92 | 2020-06-01 | 2020-06-23 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Cannabidiol, Bortezomib, Leucovorin - Cancer of Pancreas, Cancer of Liver | Phase 1 / Phase 2 | Unknown | Leaf Vertical Inc. | 160 | 2019-01-15 | 2018-07-31 |
| Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration Shortened hydration time and dispensary of Akynzeo, Standard of care - Gallbladder Cancer | Phase 2 | Unknown | Imperial College Healthcare NHS Trust | 30 | 2019-01-02 | 2022-07-15 |
| Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Apatinib, Tegafur - Gallbladder Carcinoma | Phase 2 | Unknown | Eastern Hepatobiliary Surgery Hospital | 138 | 2018-08-10 | 2018-10-11 |
| A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism Rivaroxaban, Dalteparin, apixaban - Cancer-associated Thrombosis, Esophageal Cancer | Phase 2 | Unknown | Asan Medical Center | 176 | 2017-08-07 | 2020-01-06 |
| Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma conventional chemotherapy(FORFIRINOX) combined with target agents, conventional chemotherapy(FORFIRINOX) - Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 150 | 2016-11-01 | 2018-12-07 |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma biological test, GEMOX, Cetuximab - Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 152 | 2016-07-01 | 2018-05-07 |
| Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma mutation and signal pathway activation status analysis Drug: FORFIRINOX - Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 100 | 2016-07-01 | 2018-12-11 |
| A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Fluorouracil implant - Gallbladder Cancer, Bile Duct Cancer | Phase 2 | Unknown | Simcere Pharmaceutical Co., Ltd | 100 | 2010-06-01 | 2011-03-17 |
| HAI Via Interventionally Implanted Port Catheter Systems interventionally implanted hepatic arterial port catheter - Colorectal Cancer, Liver Neoplasms | Phase 2 | Unknown | Charite University, Berlin, Germany | 100 | 2002-04-01 | 2006-07-25 |
| Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer filgrastim, pegylated liposomal doxorubicin hydrochloride - Extrahepatic Bile Duct Cancer, Gallbladder Cancer | Phase 2 | Unknown | Brown University | 26 | 1998-01-01 | 2013-12-19 |
Cholangiocarcinoma (4) · Bile Duct Neoplasms (3) · Carcinoma, Hepatocellular (3) · Liver Neoplasms (3) · Biliary Tract Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Duodenal Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Klatskin Tumor (1)
Biliary Tract Diseases (16) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Gallbladder Diseases (16) · Neoplasms (16) · Neoplasms by Site (16) · Biliary Tract Neoplasms (14) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Adenocarcinoma (6) · Carcinoma (5) · Liver Diseases (4) · Bile Duct Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3)
Drug Therapy (2) · Everolimus (2) · Fluorouracil (2) · Oxaliplatin (2) · Standard of Care (2) · Bevacizumab (1) · Bortezomib (1) · Cannabidiol (1) · Cetuximab (1) · Crizotinib (1) · Dalteparin (1) · Filgrastim (1) · Gefitinib (1) · Gemcitabine (1) · Immunotherapy (1)
Shanghai Jiao Tong University School of Medicine (3) · Eastern Hepatobiliary Surgery Hospital (2) · Asan Medical Center (1) · Banaras Hindu University (1) · Brown University (1) · Charite University, Berlin, Germany (1) · Imperial College Healthcare NHS Trust (1) · Leaf Vertical Inc. (1) · Peking Union Medical College Hospital (1) · Simcere Pharmaceutical Co., Ltd (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (9) · United States (2) · Germany (1) · India (1) · South Korea (1) · United Kingdom (1)
Bert Hildebrandt, MD (1) · Haitao Zhao, MD (1) · Hanno Riess, MD, PhD (1) · Harpreet Wasan, MD (1) · Howard Safran, MD (1) · Jens Ricke, MD, PhD (1) · Ming Kuang, PhD (1) · Peter Neuhaus, MD, PhD (1) · Roland Felix, MD, PhD (1) · Sarah F Katta, DO (1) · Zhengang Yuan, PhD (1)
PMID 20375404, PMID 24769639, PMID 24852116, PMID 26179201, PMID 26598942, PMID 27095655, PMID 27234522, PMID 27806234, PMID 28818953, PMID 29341833, PMID 29433850, PMID 29882997, PMID 30515783, PMID 30642373, PMID 30646854, PMID 30755690, PMID 30811474, PMID 31081949, PMID 31403867, PMID 31407173, PMID 31501784, PMID 33198671, PMID 34172290, PMID 40638104